Jian Min Lin
About Jian Min Lin
Jian Min Lin is an Executive Director at Tenaya Therapeutics, where he has worked since 2021. He has extensive experience in pharmacology and toxicology, with previous roles at FibroGen, Morphotek/Eisai, and Spark Therapeutics.
Current Role at Tenaya Therapeutics
Jian Min Lin serves as the Executive Director at Tenaya Therapeutics, a position he has held since 2024. In this role, he oversees pharmacology and toxicology initiatives, contributing to the company's research and development efforts. Prior to this, he was the Senior Director of Pharmacology and Toxicology at the same organization, starting in 2021. His tenure at Tenaya Therapeutics has been marked by a focus on advancing therapeutic solutions in the biotechnology sector.
Previous Experience in Pharmacology and Toxicology
Before joining Tenaya Therapeutics, Jian Min Lin held various positions in pharmacology and toxicology. He worked at Morphotek/Eisai as the Director of Pharmacology/Toxicology from 2008 to 2016, where he managed key projects in drug development. He also served as the Pharmacology and Toxicology Lead at Spark Therapeutics, Inc. from 2016 to 2017. Additionally, he was an Associate Director of Pharmacology at FibroGen for one year in 2007-2008, gaining valuable experience in the pharmaceutical industry.
Consulting Experience
Jian Min Lin worked as a Senior Consultant at Fenix Group International, LLC from 2018 to 2021. In this role, he provided expert guidance on pharmacological strategies and toxicology assessments, leveraging his extensive background in the field. His consulting experience complemented his directorial roles, enhancing his understanding of industry needs and challenges.
Educational Background
Jian Min Lin has a robust educational background in medicine and science. He studied at Stony Brook University, where he earned a Ph.D. in biochemistry and tumor biology from 1987 to 1992. He furthered his education at Harvard Medical School, completing a fellowship from 1992 to 1994. Additionally, he studied pediatrics at Jiaotong University Medical School, equipping him with a diverse knowledge base relevant to his career.
Career Timeline
Jian Min Lin's career spans several key roles in pharmacology and toxicology. After completing his education, he began his professional journey at FibroGen in 2007. He then transitioned to Morphotek/Eisai in 2008, where he worked for eight years. Following this, he joined Spark Therapeutics for a year before taking on a consulting role at Fenix Group International. In 2018, he joined Tenaya Therapeutics as Director of Pharmacology and Toxicology, progressing to Senior Director in 2021 and then to Executive Director in 2024.